Effects of Losartan on Hepatic Fibrogenesis in Chronic Hepatitis C
Phase 4
Completed
- Conditions
- Chronic Hepatitis CLiver Fibrosis
- Registration Number
- NCT00298714
- Lead Sponsor
- Hospital Clinic of Barcelona
- Brief Summary
There is evidence on the beneficial effects of the administration of angiotensin II type 1 (AT1) receptors antagonists on liver fibrosis in hepatic stellate cells, experimental models of liver fibrosis in rodents and limited information in chronic hepatitis C with mild fibrosis.
The purpose of this study is to investigate the effect of long-term administration of oral Losartan, an AT1 receptor antagonist, on liver fibrogenesis in patients with chronic hepatitis C and fibrosis F2-F3 (METAVIR score).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
- age between 35 and 65 years
- chronic hepatitis C with intermediate fibrosis (F2-F3 in Metavir score).
- non-responder or contraindication to antiviral therapy.
Read More
Exclusion Criteria
- any other cause of liver disease
- HIV positive
- alcohol consumption
- arterial hypertension
- creatinine > 1.5mg/dL
- treatment with AT1 receptor antagonists or angiotensin converting enzyme inhibitors in the past 12 months.
- antiviral therapy in the past 12 months
- contraindications to oral losartan
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Assessment of liver fibrogenesis by changes in gene expression of key mediators of liver fibrosis.
- Secondary Outcome Measures
Name Time Method